A Randomized, Open-Label, Crossover Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir Administered Concurrently in Healthy Adult Subjects
Latest Information Update: 07 Sep 2023
At a glance
- Drugs Lamivudine/maraviroc/zidovudine (Primary) ; Lamivudine/zidovudine; Maraviroc
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 18 May 2012 New trial record